Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

The FDA has rejected Sanofi's application seeking approval of tolebrutinib to treat certain forms of MS in its present form.

Sanofi (SNY) announced on Wednesday that the U.S. FDA issued a complete response letter regarding its marketing application ...

Monoclonal antibody DMTs, especially anti-CD20 therapies, effectively prevent relapses but have limited impact on progressive MS. Progressive MS involves compartmentalized CNS inflammation, with ...

Scientists in Germany are cautiously optimistic about new multiple sclerosis therapy possibilities after decoding the functions of two crucial proteins. Multiple sclerosis (MS) is a disease in which ...

According to the federal government's National Institute of Neurological Disorders and Stroke, nearly 3 million people worldwide - with almost a third in the United States - are living with multiple ...

Multiple sclerosis (MS) is a debilitating disease that currently has no cure, but scientists may have uncovered a new therapy involving a lipid that regulates inflammation. Tests in mice showed that ...

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...

STOCKHOLM ― Until their mid to late 30s, some people with multiple sclerosis (MS) can better compensate for damage to their central nervous system, new evidence suggests. Thereafter, at about age 40, ...